Robert L. Medcalf

Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation.

Prothrombin G20210A is a bifunctional gene polymorphism.

Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration.

Inherent instability of plasminogen activator inhibitor type 2 mRNA is regulated by tristetraprolin.

The structure of the zinc finger domain from human splicing factor ZNF265 fold.

The t-PA -7351C>T enhancer polymorphism decreases Sp1 and Sp3 protein binding affinity and transcriptional responsiveness to retinoic acid.

The relationship between the prothrombin upstream sequence element and the G20210A polymorphism: the influence of a competitive environment for mRNA 3'-end formation.

Transcriptional and posttranscriptional regulation of the plasminogen activator system.

Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury.

Regulation of protease and protease inhibitor gene expression: the role of the 3'-UTR and lessons from the plasminogen activating system.

Meet the serpins.

The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2.

Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity.

SerpinB2 is an inducible host factor involved in enhancing HIV-1 transcription and replication.

Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo.

Stage specific gene expression of serpins and their cognate proteases during myeloid differentiation.

Two conserved regions within the tissue-type plasminogen activator gene promoter mediate regulation by brain-derived neurotrophic factor.

Desmoteplase-mediated plasminogen activation and clot lysis are inhibited by the lysine analogue tranexamic acid.

Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function.

A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury.

Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.

The plasminogen activator inhibitor 2 transcript is destabilized via a multi-component 3' UTR localized adenylate and uridylate-rich instability element in an analogous manner to cytokines and oncogenes.

Thrombin-induced activation of astrocytes in mixed rat hippocampal cultures is inhibited by soluble thrombomodulin.

Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction.

Desmoteplase: discovery, insights and opportunities for ischaemic stroke.

Plasminogen activator inhibitor type 2: still an enigmatic serpin but a model for gene regulation.

Plasminogen activation-based thrombolysis for ischaemic stroke: the diversity of targets may demand new approaches.

t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes.

Role of histone acetylation in the stimulatory effect of valproic acid on vascular endothelial tissue-type plasminogen activator expression.

Plasminogen activation and thrombolysis for ischemic stroke.

Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain.

The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans.

Tissue plasminogen activator does not alter development of acquired epilepsy.

Nucleocytoplasmic coagulation: an injury-induced aggregation event that disulfide crosslinks proteins and facilitates their removal by plasmin.

Plasminogen-stimulated inflammatory cytokine production by airway smooth muscle cells is regulated by annexin A2.

Tissue-type plasminogen activator is an extracellular mediator of Purkinje cell damage and altered gait.